2-chloropropylamine hydrochloride | 6266-35-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: 2-chloropropylamine hydrochloride
• 英文别名: 2-chloropropylazanium;chloride
• CAS: 6266-35-9
• 化学式: C₃H₈ClN*ClH
• mdl: MFCD18976962
• 分子量: 130.017
• InChiKey: VSBDRUDRPGMLHR-UHFFFAOYSA-N

物化性质

• 熔点：
  180-181 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.46
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloropropylamine hydrochloride 在 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 以52%的产率得到2-甲基-1H-咪唑-1-丙胺
  参考文献：
  名称：

  Benzoxazole carboxamides for treating CINV and IBS-D

  摘要：

  公式I和II的化合物： 被披露为5-HT3受体拮抗剂。那些表现出中枢活性的化合物对治疗CINV有用；那些抑制外周受体的化合物对治疗IBS-D有用。

  公开号：

  US20060183769A1
• 作为产物：
  描述：

  异丙醇胺 在 盐酸 、 氯化亚砜 作用下， 生成 2-chloropropylamine hydrochloride
  参考文献：
  名称：

  Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

  摘要：

  这项发明涉及2-芳基亚胺杂环化合物，包括2-芳基亚胺-1,3-噻唑啉、2-芳基亚胺-2,3,4,5-四氢-1,3-噻嗪、2-芳基亚胺-1,3-噻唑啉-4-酮、2-芳基亚胺-1,3-噻唑啉-5-酮和2-芳基亚胺-1,3-噁唑啉，以及它们在调节孕激素受体介导的过程中的应用，以及用于这类治疗的药物组合物。

  公开号：

  US06353006B1

文献信息

• MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1302463A1

  公开（公告）日：2003-04-16

  Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided. 3,5-Dicyanopyridine derivatives or their salts.

  基于K通道开放效应具有高导电型钙激活K通道开放效应和平滑肌松弛作用的化合物，可用于治疗尿频和尿失禁。提供3,5-二氰基吡啶衍生物或其盐。
• Substituted furan compounds and pharmaceutical compositions containing
  申请人：Glaxo Group Limited

  公开号：US04288443A1

  公开（公告）日：1981-09-08

  The invention relates to compounds of the general formula ##STR1## and physiologically acceptable salts and N-oxides, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2 which may be the same or different each represent hydrogen, C.sub.1-8 alkyl, C.sub.4-8 cycloalkyl, C.sub.3-6 alkenyl, aralkyl with 1 to 4 carbon atoms in the alkyl residue or C.sub.1-8 alkyl interrupted by an oxygen atom or a group ##STR2## in which R.sub.5 represents hydrogen or C.sub.1-8 alkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached, form a saturated monocyclic 5 to 7 membered heterocyclic ring which may additionally contain the heterofunction O or ##STR3## R.sub.3 represents straight or branched chain C.sub.1-8 alkyl, alkoxyalkyl with 1 to 8 carbon atoms in each alkyl residue, C.sub.1-8 hydroxyalkyl, C.sub.1-8 alkoxycarbonyl, alkyl thioalkyl with 1 to 8 carbon atoms in each alkyl residue, halogen or aryl; R.sub.4 represents hydrogen, C.sub.1-8 alkyl, C.sub.3-6 alkenyl or alkoxyalkyl with 1 to 8 carbon atoms in each alkyl residue; X represents --O-- or --S--; Y represents .dbd.S, .dbd.O, .dbd.NR.sub.6 or .dbd.CHNO.sub.2 where R.sub.6 represents hydrogen, nitro, cyano, C.sub.1-8 alkyl, aryl, C.sub.1-8 alkylsulphonyl or arylsulphonyl; m represents an integer from 2 to 4 inclusive; and n represents an integer which is 1 or 2, or additionally when X is --S-- n may also be zero. The invention also relates to processes for the production of such compounds, pharmaceutical compositions containing them and certain novel intermediates used in their production, i.e. amines of the formula ##STR4## and alcohols of the formula ##STR5## The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

  该发明涉及一般公式##STR1##的化合物，以及其生理上可接受的盐和N-氧化物、水合物和生物前体，其中R.sub.1和R.sub.2可以相同也可以不同，每个代表氢、C.sub.1-8烷基、C.sub.4-8环烷基、C.sub.3-6烯基、含有1至4个碳原子的烷基残基的芳基烷基或被氧原子或基团##STR2##打断的C.sub.1-8烷基，其中R.sub.5代表氢或C.sub.1-8烷基，或者R.sub.1和R.sub.2可以与它们连接的氮原子一起形成饱和的单环5到7成员杂环环，还可以额外含有杂原子O或##STR3##，R.sub.3代表直链或支链C.sub.1-8烷基、在每个烷基残基中含有1至8个碳原子的烷氧烷基、C.sub.1-8羟基烷基、C.sub.1-8烷氧羰基、在每个烷基残基中含有1至8个碳原子的烷基硫烷基、卤素或芳基；R.sub.4代表氢、C.sub.1-8烷基、C.sub.3-6烯基或在每个烷基残基中含有1至8个碳原子的烷氧烷基；X代表--O--或--S--；Y代表.dbd.S、.dbd.O、.dbd.NR.sub.6或.dbd.CHNO.sub.2，其中R.sub.6代表氢、硝基、氰基、C.sub.1-8烷基、芳基、C.sub.1-8烷基磺酰基或芳基磺酰基；m表示一个从2到4的整数；n表示一个整数，可以是1或2，或者当X为--S--时，n也可以为零。该发明还涉及生产这种化合物的过程，含有它们的药物组合物以及在其生产中使用的某些新颖中间体，即一般式##STR4##的胺和一般式##STR5##的醇。式(I)的化合物显示作为选择性组织胺H.sub.2-拮抗剂的药理活性。
• Process for producing 2-mercaptoethylamine hydrohalides
  申请人：Mitsui Toatsu Chemicals, Inc.

  公开号：US04507500A1

  公开（公告）日：1985-03-26

  A process for producing 2-mercaptoethylamine hydrohalides of the general formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are identical or different, and each represents a hydrogen atom, a lower alkyl group, a hydroxy-substituted lower alkyl group or a phenyl group, and X represents a halogen atom, which comprises reacting a 2-mercaptothiazoline of the general formula ##STR2## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined above, with a 2-halogenoethylamine hydrohalide of the general formula ##STR3## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and X are as defined above, in the presence of water.

  一种生产一般式为##STR1##的2-巯基乙胺氢卤化物的方法，其中R.sub.1，R.sub.2，R.sub.3和R.sub.4相同或不同，每个代表氢原子，低烷基基团，羟基取代的低烷基基团或苯基，X代表卤素原子，包括在水的存在下反应一般式为##STR2##的2-巯基噻唑啉（其中R.sub.1，R.sub.2，R.sub.3和R.sub.4如上定义），与一般式为##STR3##的2-卤代乙基胺氢卤化物（其中R.sub.1，R.sub.2，R.sub.3，R.sub.4和X如上定义）反应。
• A Convenient Method to Synthesize 1,3-Selenazolidin-2-ones from 2-Chloroethyl Amine Salts by Se/CO System under Atmospheric Pressure and Temperature
  作者：Fengshou Tian、Yahong Chen、Peng Li、Shiwei Lu

  DOI：10.1002/hc.21127

  日期：2013.11

  1,3-Selenazolidin-2-ones were successfully synthesized by the reaction of 2-chloroethyl amine salts with the Se/CO system via selenation and carbonylation in the presence of NaOH under atmospheric pressure and temperature, and were characterized by gas chromatography-mass spectrometry and nuclear magnetic resonance. (C) 2013 Wiley Periodicals, Inc.

  2-氯乙胺盐与Se/CO体系在常压常温常压常温下，在NaOH存在下通过硒化和羰基化反应成功合成了1,3-硒唑啉-2-酮类化合物，并进行了气相色谱-质谱表征。光谱和核磁共振。(C) 2013 Wiley Periodicals, Inc.
• Study on the Isolation and Chemical Investigation of Potential Impurities in Dexrazoxane Using 2D-NMR and LC-PDA-MS
  作者：Vinodh Guvvala、Venkatesan Chidambaram Subramanian、Jayashree Anireddy、Mahesh Konda

  DOI：10.1021/acs.oprd.6b00219

  日期：2017.1.20

  performed. The degradation product of dexrazoxane is known in the literature; however, the information related to process impurities is not available. For the first time, two process related impurities were isolated, characterized, and confirmed by their individual chemical synthesis. The present study describes the isolation methods of the impurities and their structural elucidation using IR, 1H, 13C

  进行了与右雷佐生的合成有关的工艺相关杂质的化学研究。右雷佐生的降解产物在文献中是已知的。但是，有关工艺杂质的信息不可用。首次分离，表征和鉴定了两个与过程相关的杂质，并通过它们各自的化学合成进行了确认。本研究描述了使用IR，1 H，13 C，2D NMR和质谱对杂质进行分离的方法及其结构解析。这些杂质的鉴定对于右雷佐生原料药生产过程中的质量控制将非常有价值。